Does Rallies show 13F holders for CRL?

Yes. Rallies tracks hedge fund and 13F ownership data for CRL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CRL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRL. It does not provide personalized investment advice.

CRL (Charles River Laboratories International, Inc.) Stock Analysis - Hedge Fund Holdings

Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of May 21, 2026, CRL trades at $156.24 with a market cap of $7.22B and a P/E ratio of -41.91. CRL moved +2.47% today. Year to date, CRL is -25.10%; over the trailing twelve months it is +8.71%. Its 52-week range spans $91.86 to $230.02. Analyst consensus is buy with an average price target of $205.38. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CRL stock?

Hedge funds tracked by Rallies that own CRL include Harris Associates, D1 Capital, Redmile Group, Pinebridge Investments, and Maverick Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Charles River Laboratories International, Inc..

CRL Key Metrics

Key financial metrics for CRL
Metric	Value
Price	$156.24
Market Cap	$7.22B
P/E Ratio	-41.91
EPS	$-3.70
Dividend Yield	0.00%
52-Week High	$230.02
52-Week Low	$91.86
Volume	747.46K
Avg Volume	0
Revenue (TTM)	$4.03B
Net Income	$-182.84M
Gross Margin	0.00%

Top Hedge Funds Holding CRL

Harris Associates holds 2.15M shares of CRL, changed +28.36% as of Mar 31, 2026.
D1 Capital holds 777.49K shares of CRL, changed -16.92% as of Mar 31, 2025.
Redmile Group holds 86.78K shares of CRL, changed +0.00% as of Dec 31, 2023.
Pinebridge Investments holds 17.03K shares of CRL, changed -84.88% as of Mar 31, 2025.
Maverick Capital holds 8.18K shares of CRL, changed +0.00% as of Mar 31, 2026.

Latest CRL News

Charles River shares rise after Q1 2026 results, guidance reaffirmed, divestiture completed — May 7, 2026
CRL jumps as CEO transition takes effect ahead of May 7 earnings catalyst — May 5, 2026
Charles River Labs jumps as bullish analyst catalyst hits ahead of May 7 earnings — May 4, 2026
Charles River (CRL) drops as divestiture-driven 2026 revenue cut and layoffs weigh — Apr 28, 2026
Charles River slips ahead of May earnings as divestiture-driven revenue reset hangs over 2026 outlook — Apr 23, 2026

Recent CRL Insider Trades

LaPlume Joseph W bought 25 (~$4.36K) on Mar 3, 2026.
LaPlume Joseph W sold 400 (~$65.49K) on Aug 22, 2025.
LaPlume Joseph W sold 800 (~$126.08K) on Aug 18, 2025.

CRL Analyst Consensus

10 analysts cover CRL: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $205.38.

Common questions about CRL

Who owns CRL stock?: Hedge funds tracked by Rallies that own CRL include Harris Associates, D1 Capital, Redmile Group, Pinebridge Investments, and Maverick Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Charles River Laboratories International, Inc..
Does Rallies show 13F holders for CRL?: Yes. Rallies tracks hedge fund and 13F ownership data for CRL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CRL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRL. It does not provide personalized investment advice.